Susana Banerjee

Articles

Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201

December 17th 2024

Professor Susana Banerjee presents the ENGOT-OV60/GOG-3052/RAMP 201 study, highlighting the efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer.